Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunshine Study of 12-week home self-infusion with Prolastin in severe alpha-1 antitrypsin deficiency
2024-515894-80-00Phase 3Authorised
- Sponsor
- Grifols
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Grifols. Primary endpoint: Occurrence of adverse events. Planned start Jul 2025; status: authorised.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2024-515894-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515894-80-00.